Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 3, 2008
Continuing Genentech's Herceptin - Confirming What We Suspected
Analysis of: Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Many of us oncologists have been in the practice of continuing  Herceptin (Trastuzumab) even when the breast cancer we were treating was growing while on the drug.  Now, this randomized study gives data to back up that practice.
June 2, 2008
A New Algorithm Will be Needed to Calculate Market Sharee
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
June 2, 2008
Can Glaxo’s Affymetrix Microarray Predict Who Will Benefit from its MAGE-A3 Immunotherapy?
Analysis of: New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma | www.pipelinereview.com
Author: GLG Expert Contributor
This describes a potential two-step process using modern molecular biology to customize cancer therapy. First the Affymetrix Microarray analyzes tumor genes to try to identify which patients are at high risk to have a cancer recurrence following lung cancer surgery. Second, Glaxo's MAGE-A3 proprietary...
June 2, 2008
ImClone: One study shot down. The other??
Analysis of: Drug Brings ImClone in From Cold | online.wsj.com
Author: GLG Expert Contributor
Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
June 2, 2008
Erbitux (ImClone):1 month and <10% additional survival in lung cancer. Not very impressive!
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival
May 29, 2008
Glaxo's Promacta Hits a Snag with the FDA
Analysis of: FDA says Glaxo drug fails to control bleeding | seattletimes.nwsource.com
Author: GLG Expert Contributor
Apparently, the FDA was not impressed enough with the data for Promacta (eltrombopag) for the treatment of ITP, a common and potentially serious auto-immune bleeding disorder involving platelets.  Citing a lack of "robust evidence" from several studies, the FDA will be seeking further opinions...
May 27, 2008
Revlimid (Celgene) in CLL- not a bad addition in our therapeutic algorithm
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.
May 27, 2008
So much for non-invasive surgery in prostate cancer
Analysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: GLG Expert Contributor
Higher recurrance rate???!!!
May 27, 2008
Genentech, Schering-Plough,,Avant Immunotherapeutics. & Pfizer all helping with "brain cancer" therapy.
Analysis of: Hints of Progress in Drugs Treating Brain Cancer | www.nytimes.com
Author: GLG Expert Contributor
     While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) &  Avant/Pfizer  vaccines  are making an impact on  "Brain Cancer"  survival.
May 22, 2008
Erbitux: Alot remains to be determined re: its place in NSCLCA therapy
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: GLG Expert Contributor
" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 435

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-10-12T01:47:01.177